Golikova spoke about the tests of the vaccine "Vector" from COVID-19

“At the end of September, we plan to complete clinical trials of another Russian-made vaccine at the State Research Center“ Vector ”. This vaccine based on peptide antigens was named "EpiVacCorona". To date, according to the results of ongoing clinical trials of the first and second stages, there are no complications in the vaccinated, ”Golikova said.

Earlier, the Ministry of Health of Russia issued the N.N. Gamaleya permission to conduct post-marketing studies of the COVID-19 vaccine.

The director of the Gamaleya Center, Alexander Gintsburg, also noted that the civil circulation of the COVID-19 vaccine could begin a month after the start of the third, post-registration stage of drug research.